The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.

J. Shaffer,J. Houston

DOI: https://doi.org/10.1111/J.1365-2125.1985.TB02682.X

1985-04-01

British Journal of Clinical Pharmacology

Abstract:

What problem does this paper attempt to address?

Celiac Disease and Neurological Manifestations: From Gluten to Neuroinflammation

Mauro Giuffrè,Silvia Gazzin,Caterina Zoratti,John Paul Llido,Giuseppe Lanza,Claudio Tiribelli,Rita Moretti

DOI: https://doi.org/10.3390/ijms232415564

2022-12-08

Abstract:Celiac disease (CD) is a complex multi-organ disease with a high prevalence of extra-intestinal involvement, including neurological and psychiatric manifestations, such as cerebellar ataxia, peripheral neuropathy, epilepsy, headache, cognitive impairment, and depression. However, the mechanisms behind the neurological involvement in CD remain controversial. Recent evidence shows these can be related to gluten-mediated pathogenesis, including antibody cross-reaction, deposition of immune-complex, direct neurotoxicity, and in severe cases, vitamins or nutrients deficiency. Here, we have summarized new evidence related to gut microbiota and the so-called "gut-liver-brain axis" involved in CD-related neurological manifestations. Additionally, there has yet to be an agreement on whether serological or neurophysiological findings can effectively early diagnose and properly monitor CD-associated neurological involvement; notably, most of them can revert to normal with a rigorous gluten-free diet. Moving from a molecular level to a symptom-based approach, clinical, serological, and neurophysiology data might help to disentangle the many-faceted interactions between the gut and brain in CD. Eventually, the identification of multimodal biomarkers might help diagnose, monitor, and improve the quality of life of patients with "neuroCD".
Potential therapeutic options for celiac Disease: An update on Current evidence from Gluten-Free diet to cell therapy

Effat Noori,Nader Hashemi,Delsuz Rezaee,Reza Maleki,Forough Shams,Bahram Kazemi,Mojgan Bandepour,Fardin Rahimi

DOI: https://doi.org/10.1016/j.intimp.2024.112020

IF: 5.714

2024-04-13

International Immunopharmacology

Abstract:Celiac disease (CD) is a chronic autoimmune enteropathy and multifactorial disease caused by inappropriate immune responses to gluten in the small intestine. Weight loss, anemia, osteoporosis, arthritis, and hepatitis are among the extraintestinal manifestations of active CD. Currently, a strict lifelong gluten-free diet (GFD) is the only safe, effective, and available treatment. Despite the social burden, high expenses, and challenges of following a GFD, 2 to 5 percent of patients do not demonstrate clinical or pathophysiological improvement. Therefore, we need novel and alternative therapeutic approaches for patients. Innovative approaches encompass a broad spectrum of strategies, including enzymatic degradation of gluten, inhibition of intestinal permeability, modulation of the immune response, inhibition of the transglutaminase 2 (TG2) enzyme, blocking antigen presentation by HLA-DQ2/8, and induction of tolerance. Hence, this review is focused on comprehensive therapeutic strategies ranging from dietary approaches to novel methods such as antigen-based immunotherapy, cell and gene therapy, and the usage of nanoparticles for CD treatment.

pharmacology & pharmacy,immunology
Beyond the gluten-free diet: Innovations in celiac disease therapeutics

Sara Massironi,Marianna Franchina,Alessandra Elvevi,Donatella Barisani

DOI: https://doi.org/10.3748/wjg.v30.i38.4194

IF: 5.374

2024-10-14

World Journal of Gastroenterology

Abstract:Celiac disease (CD) is an autoimmune disorder exacerbated by the ingestion of gluten in genetically susceptible individuals, leading to intestinal inflammation and damage. This chronic disease affects approximately 1% of the world’s population and is a growing health challenge due to its increasing prevalence. The development of CD is a complex interaction between genetic predispositions and environmental factors, especially gluten, culminating in a dysregulated immune response. The only effective treatment at present is a strict, lifelong gluten-free diet. However, adherence to this diet is challenging and often incomplete, so research into alternative therapies has intensified. Recent advances in understanding the molecular and immunological aspects of CD have spearheaded the development of novel pharmacologic strategies that should provide more effective and manageable treatment options. This review examines the latest innovations in CD therapies. The focus is on drugs in advanced clinical phases and targeting specific signaling pathways critical to the disease pathogenesis. We discuss both quantitative strategies such as enzymatic degradation of gluten, and qualitative approaches including immunomodulation and induction of gluten tolerance. Innovative treatments currently under investigation include transglutaminase inhibitors, which prevent the modification of gluten peptides, and nanoparticle-based therapies to recalibrate the immune response. These new therapies not only promise to improve patient outcomes but are also expected to improve quality of life by reducing the burden of dietary restrictions. The integration of these new therapies could revolutionize the treatment of CD and shift the paradigm from strict dietary restrictions to a more flexible and patient-friendly therapeutic approach. This review provides a comprehensive overview of the future prospects of CD treatment and emphasizes the importance of continued research and multidisciplinary collaboration to integrate these advances into standard clinical practice.

gastroenterology & hepatology
Cross-Talk Between Gluten, Intestinal Microbiota and Intestinal Mucosa in Celiac Disease: Recent Advances and Basis of Autoimmunity

Atul Munish Chander,Hariom Yadav,Shalini Jain,Sanjay Kumar Bhadada,Devinder Kumar Dhawan

DOI: https://doi.org/10.3389/fmicb.2018.02597

IF: 5.2

2018-11-01

Frontiers in Microbiology

Abstract:Celiac disease (CD) is an autoimmune disorder of the small intestine, caused by gluten induced inflammation in some individuals susceptible to genetic and environmental influences. To date, pathophysiology of CD in relation to intestinal microbiota is not known well. This review relies on contribution of intestinal microbiome and oral microbiome in pathogenesis of CD based on their interactions with gluten, thereby highlighting the role of upper gastrointestinal microbiota. It has been hypothesized that CD might be triggered by additive effects of immunotoxic gluten peptides and intestinal dysbiosis (microbial imbalance) in the people with or without genetic susceptibilities, where antibiotics may be deriving dysbiotic agents. In contrast to the intestinal dysbiosis, genetic factors even seem secondary in disease outcome thus suggesting the importance of interaction between microbes and dietary factors in immune regulation at intestinal mucosa. Moreover, association of imbalanced counts of some commensal microbes in intestine of CD patients suggests the scope for probiotic therapies. <i>Lactobacilli</i> and specific intestinal and oral bacteria are potent source of gluten degrading enzymes (glutenases) that may contribute to commercialization of a novel glutenase therapy. In this review, we shall discuss advantages and disadvantages of food based therapies along with probiotic therapies where probiotic therapies are expected to emerge as the safest biotherapies among other in-process therapies. In addition, this review emphasizes on differential targets of probiotics that make them suitable to manage CD as along with glutenase activity, they also exhibit immunomodulatory and intestinal microbiome modulatory properties.

microbiology
Celiac disease 2015 update: new therapies

Gopal Veeraraghavan,Daniel A Leffler,Dharmesh H Kaswala,Rupa Mukherjee

DOI: https://doi.org/10.1586/17474124.2015.1033399

Abstract:Celiac disease (CD) is a chronic, small intestinal, immune-mediated enteropathy triggered by exposure to dietary gluten in genetically susceptible individuals. Currently, lifelong adherence to a gluten-free diet (GFD) is the only available treatment. However, GFD alone is not sufficient to relieve symptoms, control small intestinal inflammation and prevent long-term complications in many patients. The GFD has its challenges including issues related to adherence, lifestyle restrictions and cost. As a result, there is growing interest in and a need for non-dietary therapies to manage this condition. In recent years, different targets in the immune-mediated cascade of CD have been identified in clinical and pre-clinical trials for potential therapies. This review will discuss the latest non-dietary therapies in CD, including endopeptidases, modulators of enterocyte tight junctions and agents involved in gluten tolerization and immunomodulation. We will also discuss the potential implications of approved therapeutics on CD clinical practice.
The Interaction Between Celiac Disease and Intestinal Microbiota

Giuseppe Losurdo,Mariabeatrice Principi,Andrea Iannone,Enzo Ierardi,Alfredo Di Leo

DOI: https://doi.org/10.1097/mcg.0000000000000682

2016-11-01

Journal of Clinical Gastroenterology

Abstract:Celiac disease (CD) is the most common autoimmune enteropathy, triggered by a deregulated immune response to gliadin. It has been hypothesized that human intestinal microbiota may interfere with the pathogenesis of the disease and in the clinical course of CD. In the present review, we analyzed the microbiota alterations observed in the course of CD, how they may influence the pathogenesis of CD, and the possible applications for a microbiota modulation in CD. In detail, most of the current literature underlined that the dysbiosis in CD is hallmarked by an increase in gram-negative and Bacteroidetes species, and by a decrease in Bifidobacteria and Lactobacilli. As the intestinal microbiota is able to modulate the cytokine environment, an unfavorable microbiota could amplify the immune response to gliadin in individuals with CD, whereas the administration of probiotic species could lead to a decrease in proinflammatory cytokine production. Therefore, dysbiosis could represent an important trigger in CD pathogenesis, along with genetic (HLA-haplotypes) and environmental factors (antibiotic administration, mode of delivery, and breastfeeding). Although data on the modulation of microbiota by GFD are conflicting, current evidence has demonstrated that probiotic administration could be useful to improve symptoms and to reduce molecular mucosal inflammation, by downregulating the cytokines involved in CD pathogenesis. However, studies analyzing this aspect are few in number, thus stimulating the exploration of this field, with the aim of achieving a solid pathophysiological basis for probiotic administration in CD.

gastroenterology & hepatology
Interaction between Gut Microbiota and Celiac Disease: From Pathogenesis to Treatment

Roberta Elisa Rossi,Giulia Dispinzieri,Alessandra Elvevi,Sara Massironi

DOI: https://doi.org/10.3390/cells12060823

IF: 6

2023-03-08

Cells

Abstract:Celiac disease (CD) is a common systemic disorder that results from an abnormal response of human immunity to gluten intake, affecting the small intestine. In individuals who carry a genetic susceptibility, CD is triggered by environmental factors, including viral infections and dysbiosis of the gut microbiota. The gut microbiome is essential in controlling the immune system, and recent findings indicate that changes in the gut microbiome may contribute to various chronic immune disorders, such as CD through mechanisms that still require further exploration. Some bacteria exhibit epitopes that mimic gliadin and may enhance an immune response in the host. Other bacteria, including Pseudomonas aeruginosa, may work in conjunction with gluten to trigger and escalate intestinal inflammation. The microbiota may also directly influence antigen development through the production of immunogenic or tolerogenic gluten peptides or directly influence intestinal permeability through the release of zonulin. Finally, the gut microbiome can impact intestinal inflammation by generating proinflammatory or anti-inflammatory cytokines and metabolites. It is crucial to consider the impact of genetic factors (specifically, HLA-DQ haplotypes), perinatal elements such as birth mode, type of infant feeding, and antibiotic and infection exposure on the composition of the early intestinal microbiome. According to the available studies, the gut microbiome alterations associated with CD tend to exhibit a decreased presence of beneficial bacteria, including some anti-inflammatory Bifidobacterium species. However, some controversy remains as some reports have found no significant differences between the gut microbiomes of individuals with and without CD. A better understanding of the gut microbiome's role in the development of CD would greatly benefit both prevention and treatment efforts, especially in complicated or treatment-resistant cases. Here, we have attempted to summarize the available evidence on the relationship between the gut microbiota and CD, with a particular focus on potential therapeutic targets.

cell biology
Probiotics, Prebiotics and Other Dietary Supplements for Gut Microbiota Modulation in Celiac Disease Patients

Giovanni Marasco,Giovanna Grazia Cirota,Benedetta Rossini,Lisa Lungaro,Anna Rita Di Biase,Antonio Colecchia,Umberto Volta,Roberto De Giorgio,Davide Festi,Giacomo Caio

DOI: https://doi.org/10.3390/nu12092674

IF: 5.9

2020-09-02

Nutrients

Abstract:To date, the only available treatment for celiac disease (CD) patients is a life-lasting gluten-free diet (GFD). Lack of adherence to the GFD leads to a significant risk of adverse health consequences. Food cross-contamination, nutritional imbalances, and persistent gastrointestinal symptoms are the main concerns related to GFD. Moreover, despite rigid compliance to GFD, patients struggle in achieving a full restoring of the gut microbiota, which plays a role in the nutritive compounds processing, and absorption. Pivotal studies on the supplementation of GFD with probiotics, such as Bifidobacterium and Lactobacilli, reported a potential to restore gut microbiota composition and to pre-digest gluten in the intestinal lumen, reducing the inflammation associated with gluten intake, the intestinal permeability, and the cytokine and antibody production. These findings could explain an improvement in symptoms and quality of life in patients treated with GFD and probiotics. On the other hand, the inclusion of prebiotics in GFD could also be easy to administer and cost-effective as an adjunctive treatment for CD, having the power to stimulate the growth of potentially health-promoting bacteria strains. However, evidence regarding the use of prebiotics and probiotics in patients with CD is still insufficient to justify their use in clinical practice.
Impact of Nutritional Profile on Gut Microbiota Diversity in Patients with Celiac Disease

Mona Soheilian-Khorzoghi,Sama Rezasoltani,Ali Moheb-Alian,Abbas Yadegar,Mohammad Rostami-Nejad,Mehdi Azizmohammad-Looha,Anil Kumar Verma,Azam Haddadi,Hossein Dabiri

DOI: https://doi.org/10.1007/s00284-022-02820-w

IF: 2.343

2022-03-14

Current Microbiology

Abstract:The pathogenesis of celiac disease (CD) is significantly influenced by gut microbiota. Daily nutritional profile influences the diversity of gut microbiota. This study was aimed to compare the abundance of gut microbiota in CD patients compared to normal control (NC), and to investigate the impact of nutritional factors on their fecal microbiota diversity. In this study, a selected panel of intestinal bacteria was assessed in 31 confirmed CD patients adhering to gluten-free diet (GFD) for more than 6 months and in 20 NC subjects. Stool samples were collected from each participant, DNA was extracted, and absolute quantitative real-time PCR (qPCR) was carried out. The gut microbiota including Bacteroidetes, Bifidobacterium, Clostridium, Staphylococcus, Enterobacteiaceae, Firmicutes, and Lactobacillus were assessed. The quantities of fruits, vegetables, meat, liquids, sugar and gluten-free candy/bread consumption were evaluated using a questionnaire. The proportion of Bifidobacterium, Firmicutes, and Lactobacillus in CD cases was significantly lower than NC (P < 0.005). Significant correlation coefficients between Bifidobacterium and Lactobacillus (P < 0.001), and also Firmicutes and Lactobacillus (P < 0.001) were recorded. Moreover, a significant association between medium amount of meat and bean consumptions and low abundance of Lactobacillus and Firmicutes (P = 0.024 and P = 0.027, respectively), and also high amount of bean consumptions and low abundance of Lactobacillus (P = 0.027) in CD were observed. The results showed that meat and bean consumptions could reduce the beneficial bacteria including Firmicutes and Lactobacillus in CD patients. Therefore, changes in the gut microbiota abundance may contribute to dietary changes and unimproved CD symptoms.

microbiology
Intestinal Microbiota and Probiotics in Celiac Disease

Luís Fernando de Sousa Moraes,Lukasz Marcin Grzeskowiak,Tatiana Fiche de Sales Teixeira,Maria do Carmo Gouveia Peluzio

DOI: https://doi.org/10.1128/cmr.00106-13

IF: 36.8

2014-07-01

Clinical Microbiology Reviews

Abstract:SUMMARY Celiac disease (CD) is a common chronic autoimmune enteropathy caused by gluten intake. To date, the only therapy for CD is the complete exclusion of dietary sources of grains and any food containing gluten. It has been hypothesized that the intestinal microbiota is somehow involved in CD. For this reason, probiotics are appearing as an interesting adjuvant in the dietetic management of CD. This review aims to discuss the characteristics of the microbiota in CD subjects and the use of probiotics as a novel therapy for CD. Comparisons between children with CD and controls show that their microbiota profiles differ; the former have fewer lactobacilli and bifidobacteria. Specific probiotics have been found to digest or alter gluten polypeptides. It has also been demonstrated that some bacterial species belonging to the genera Lactobacillus and Bifidobacterium exert protective properties on epithelial cells from damage caused by gliadin.

microbiology
New Insights into Non-Dietary Treatment in Celiac Disease: Emerging Therapeutic Options

Verónica Segura,Ángela Ruiz-Carnicer,Carolina Sousa,María de Lourdes Moreno

DOI: https://doi.org/10.3390/nu13072146

IF: 5.9

2021-06-23

Nutrients

Abstract:To date, the only treatment for celiac disease (CD) consists of a strict lifelong gluten-free diet (GFD), which has numerous limitations in patients with CD. For this reason, dietary transgressions are frequent, implying intestinal damage and possible long-term complications. There is an unquestionable need for non-dietary alternatives to avoid damage by involuntary contamination or voluntary dietary transgressions. In recent years, different therapies and treatments for CD have been developed and studied based on the degradation of gluten in the intestinal lumen, regulation of the immune response, modulation of intestinal permeability, and induction of immunological tolerance. In this review, therapeutic lines for CD are evaluated with special emphasis on phase III and II clinical trials, some of which have promising results.
The gut microbiota and celiac disease: Pathophysiology, current perspective and new therapeutic approaches

Sevda Zoghi,Amin Abbasi,Fatemah Sadeghpour Heravi,Mohammad Hossein Somi,Zeinab Nikniaz,Seyed Yaghoub Moaddab,Hamed Ebrahimzadeh Leylabadlo

DOI: https://doi.org/10.1080/10408398.2022.2121262

IF: 11.208

2022-09-28

Critical Reviews in Food Science and Nutrition

Abstract:Celiac disease (CD) as a chronic gluten-sensitive intestinal condition, mainly affects genetically susceptible hosts. The primary determinants of CD have been identified as environmental and genetic variables. The development of CD is significantly influenced by environmental factors, including the gut microbiome. Therefore, gut microbiome re-programming-based therapies using probiotics, prebiotics, postbiotics, gluten-free diet, and fecal microbiota transplantation have shown promising results in the modification of the gut microbiome. Due to the importance and paucity of information regarding the CD pathophysiology, in this review, we have covered the association between CD development and gut microbiota, the effects of infectious agents, particularly the recent Covid-19 infection in CD patients, and the efficacy of potential therapeutic approaches in the CD have been discussed. Hence, scientific literature indicates that the diverse biological functions of the gut microbiota against immunomodulatory responses have made microbiome-based therapy an alternative therapeutic paradigm to ameliorate the symptoms of CD and quality of life. However, the exact potential of microbiota-based techniques that aims to quantitatively and qualitatively alter the gut microbiota to be used in the treatment and ameliorate the symptoms of CD will be determined with further research in the future.

food science & technology,nutrition & dietetics
The use of thermal knives in surgery: electrosurgery, lasers, plasma scalpel.

J. Glover,P. Bendick,W. Link

DOI: https://doi.org/10.1016/S0011-3840(78)80017-3

IF: 2.815

Current Problems in Surgery

Abstract:
New developments in celiac disease treatments

Franziska Buriánek,Christian Gege,Petar Marinković

DOI: https://doi.org/10.1016/j.drudis.2024.104113

Abstract:Celiac disease (CeD), an autoimmune disorder triggered by gluten, affects around 1% of the global population. Standard treatment is a strict gluten-free diet (GFD), which poses significant challenges due to dietary restrictions, cross-contamination and subsequent persistent intestinal inflammation. This underscores the need for new treatment options addressing the complex pathophysiology of CeD. Recent research focuses on developing drugs that target intestinal barrier regeneration, gluten peptide modification, immune response alteration, and gut microbial ecosystem modulation. These approaches offer potential for more effective management of CeD beyond GFD. Gluten-independent treatments may be particularly relevant under the FDA's draft guidance for CeD, which emphasizes drug development as an adjunct to GFD for patients with ongoing signs and symptoms of CeD despite strict GFD.
Metabolomics and lipidomics signature in celiac disease: a narrative review

Mohammad Rostami-Nejad,Nastaran Asri,Sajjad Bakhtiari,Ensieh Khalkhal,Sepehr Maleki,Mostafa Rezaei-Tavirani,Somayeh Jahani-Sherafat,Kamran Rostami

DOI: https://doi.org/10.1007/s10238-024-01295-2

IF: 4.6

2024-02-11

Clinical and Experimental Medicine

Abstract:Celiac disease (CD) is a chronic immune-mediated inflammatory disease of the small intestine caused by aberrant immune responses to consumed gluten proteins. CD is diagnosed by a combination of the patients reported symptoms, serologic and endoscopic biopsy evaluation of the small intestine; and adherence to a strict gluten-free diet (GFD) is considered the only available therapeutic approach for this disorder. Novel approaches need to be considered for finding new biomarkers to help this disorder diagnosis and finding a new alternative therapeutic method for this group of patients. Metabolomics and lipidomics are powerful tools to provide highly accurate and sensitive biomarkers. Previous studies indicated a metabolic fingerprint for CD deriving from alterations in gut microflora or intestinal permeability, malabsorption, and energy metabolism. Moreover, since CD is characterized by increased intestinal permeability and due to the importance of membrane lipid components in controlling barrier integrity, conducting lipidomics studies in this disorder is of great importance. In the current study, we tried to provide a critical overview of metabolomic and lipidomic changes in CD.

medicine, research & experimental
Efficacy of probiotics supplementation in amelioration of celiac disease symptoms and enhancement of immune system

Mostafa Hossam-Eldin Moawad,Ibraheem M Alkhawaldeh,Abdulqadir J Naswhan

DOI: https://doi.org/10.12998/wjcc.v11.i32.7741

2023-11-16

Abstract:Patients with celiac disease (CD) have a mucosal layer that is unable to regulate the gut microbiota, leaving the host vulnerable to dangerous infections and antigens. When compared to healthy people, this dysbiosis is marked by a decrease in intra- and intergeneric biodiversity, which demonstrates an imbalance between helpful bacteria and possibly harmful or proinflammatory species. The early gut microbiota is influenced by the genotype of newborns with the HLA-DQ2 haplotypes, and this may modify how gluten is handled in the intestinal lumen, polarize innate or adaptive immune responses, and result in glutensensitive enteropathy. The outcome of gluten digestion can vary depending on the composition of the intestinal gut bacteria and the partial conversion of gluten into peptides larger than ten amino acids in the small intestines, which can be immunogenic. In the small intestine, 114 different bacterial strains belonging to 32 different species have 27 of them exhibiting peptidolytic activity. Thus, the individual risk of developing a gluten-related illness is further influenced by microbial composition and gluten degrading capacity. The conclusion that lactobacilli and Bifidobacterium spp. may be used as a probiotic supplement in CD patients is based on their shared possession of the most extensive peptidolytic and proteolytic activity thought to be engaged in the breakdown of gluten among all potential bacterial genera present in the gut microbiota. In children with CD autoimmunity, daily oral dose of Lactobacillus. plantarum HEAL9 and Lactobacillus. paracasei 8700:2 was found to modify the peripheral immune response. Bifidobacterium. breve strains have demonstrated a beneficial effect on reducing pro-inflammatory cytokine TNF- production in CD children on gluten-free diets.
Going Beyond Gluten-Free: a Review of Potential Future Therapies for Celiac Disease

Brandon Sparks,Ivor Hill,Tracy Ediger

DOI: https://doi.org/10.1007/s40746-020-00217-0

2021-01-08

Current Treatment Options in Pediatrics

Abstract:Purpose of ReviewCeliac disease is a common chronic autoimmune condition for which the only therapy currently available is strict adherence to a gluten-free diet for life. Although the diet is effective in reversing the intestinal mucosal changes, it is cumbersome to follow, is associated with some dietary deficiencies, is less palatable, and has significant quality of life implications. For all these reasons, alternatives to the gluten-free diet would greatly benefit people with celiac disease.Recent FindingsA better understanding of the pathophysiology of celiac disease has led to possible new treatments that target various steps in the development of the disease. These include intraluminal digestive enzymes and peptide-binding agents that render gluten non-toxic, drugs that modulate tight junctions between enterocytes or interfere with the inflammatory cascade that causes mucosal destruction, and agents designed to induce immune tolerance to gluten.SummaryAlthough several of these new therapeutic agents currently under investigation are showing some promise, they still need to demonstrate they are as effective and safe as the gluten-free diet before they can be recommended as an acceptable alternative for treatment of people with celiac disease. The gluten-free diet remains the only proven safe and effective treatment for celiac disease.

The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.

Celiac Disease and Neurological Manifestations: From Gluten to Neuroinflammation

Potential therapeutic options for celiac Disease: An update on Current evidence from Gluten-Free diet to cell therapy

Beyond the gluten-free diet: Innovations in celiac disease therapeutics

Cross-Talk Between Gluten, Intestinal Microbiota and Intestinal Mucosa in Celiac Disease: Recent Advances and Basis of Autoimmunity

Celiac disease 2015 update: new therapies

The Interaction Between Celiac Disease and Intestinal Microbiota

Interaction between Gut Microbiota and Celiac Disease: From Pathogenesis to Treatment

Probiotics, Prebiotics and Other Dietary Supplements for Gut Microbiota Modulation in Celiac Disease Patients

Impact of Nutritional Profile on Gut Microbiota Diversity in Patients with Celiac Disease

Intestinal Microbiota and Probiotics in Celiac Disease

New Insights into Non-Dietary Treatment in Celiac Disease: Emerging Therapeutic Options

The gut microbiota and celiac disease: Pathophysiology, current perspective and new therapeutic approaches

The use of thermal knives in surgery: electrosurgery, lasers, plasma scalpel.

New developments in celiac disease treatments

Metabolomics and lipidomics signature in celiac disease: a narrative review

Efficacy of probiotics supplementation in amelioration of celiac disease symptoms and enhancement of immune system

Going Beyond Gluten-Free: a Review of Potential Future Therapies for Celiac Disease